Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02513459 · ClinicalTrials.gov registry record · Phase 2
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT02513459 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 65 participants.
The verdict
NCT02513459, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The primary objective of the study was to investigate long-term safety of risankizumab (BI 655066/ABBV-066) in participants with moderately to severely active Crohn's disease who showed a clinical response or remission on previous treatment with risankizumab in Study NCT02031276 (BI trial 1311.6/ AbbVie M15-993) and were now receiving long-term treatment. Additional objectives of this study were to further investigate long-term efficacy, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of risankizumab.
Interventions
- DRUG Risankizumab 600 mg IV
- DRUG Risankizumab 180 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-09-16 |
| Est. Completion | 2019-06-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02513459
The ClinicalTrials.gov registry entry for NCT02513459 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risankizumab 600 mg IV is the first listed.
NCT02513459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02513459 about?
NCT02513459 is a clinical study titled "A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease". The primary objective of the study was to investigate long-term safety of risankizumab (BI 655066/ABBV-066) in participants with moderately to severely active Crohn's disease who showed a clinical response or remission on previous treatment with risankizumab in Study NCT02031276 (BI trial 1311.6/ Ab...
What is the current status of trial NCT02513459?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2015-09-16. Estimated completion is 2019-06-19.
What interventions are being tested in trial NCT02513459?
The interventions under investigation include: Risankizumab 600 mg IV (DRUG), Risankizumab 180 mg SC (DRUG).
Who is sponsoring clinical trial NCT02513459?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.